Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?

Background: Colorectal mixed adenoneuroendocrine carcinomas (MANECs) are clinically highly aggressive neoplasms. MANECs are composed of variable adenocarcinoma components combined with morphologically distinct neuroendocrine carcinoma components, which are confirmed by synaptophysin immunohistochemistry, the gold standard marker of a neuroendocrine differentiation. However, the biological behavior of adenocarcinomas that express synaptophysin but do not show a typical neuroendocrine morphology remains unclear. Methods: We investigated synaptophysin expression in 1002 conventional colorectal adenocarcinomas and correlated the results with clinicopathological characteristics and patient survival and compared the survival characteristics of synaptophysin expression groups to MANECs. Results: Synaptophysin expression in conventional colorectal adenocarcinomas was associated with a shortened disease-free survival (p = 0.037), but not with overall survival or disease-specific survival (DSS) in univariate analyses and without any survival impact in multivariate analyses. Patients with “true” MANECs, on the other hand, showed a significantly shorter survival than all conventional adenocarcinomas with or without synaptophysin expression in uni- and multivariate analyses (e.g., multivariate DSS: p < 0.001, HR: 5.20). Conclusions: Our study demonstrates that synaptophysin expression in conventional colorectal adenocarcinomas, in contrast to MANECs, is not associated with a significantly poorer clinical outcome when compared to adenocarcinomas without synaptophysin expression. Furthermore, our data suggest that conventional adenocarcinomas with a diffuse synaptophysin expression should not be classified as MANECs, also strongly arguing that synaptophysin testing should be reserved for carcinomas with an H&E morphology suggestive of a neuroendocrine differentiation.

Download Full-text

Comparison of Staging Systems of Hepatocellular Carcinoma

HPB Surgery ◽

10.1155/2011/818217 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 9

Author(s):

Yongyut Sirivatanauksorn ◽

Chutwichai Tovikkai

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

Multivariate Analyses ◽

Prognostic Index ◽

Disease Free Survival ◽

Patient Data ◽

Free Survival ◽

Staging Systems ◽

Univariate Analyses ◽

Disease Free

Many staging systems of hepatocellular carcinoma (HCC) were established; however, there is no consensus on which is proper in predicting prognosis. This study aims to evaluate various commonly used staging systems of HCC. Patients who underwent surgery during 2001–2007 were included. All patient data were retrospectively staged using six staging systems, that are American Joint Committee on Cancer (AJCC) Tumour-Node-Metastasis (TNM), Okuda staging, Cancer of the Liver Italian Program (CLIP), Barcelona Clinic Liver Cancer (BCLC), Chinese University Prognostic Index (CUPI), and Japan Integrated Staging (JIS). Child-Pugh classification was also evaluated. The staging systems were compared by mean of overall and disease-free survival. Total of 99 patient data were enrolled in the analyses. All staging systems except Okuda were significant in determining overall survival in univariate analyses. In multivariate analyses, TNM and Child-Pugh demonstrated better predictive power for overall survival. In terms of disease-free survival, univariate analyses revealed that TNM, CLIP, BCLC, CUPI, and JIS were significant, and TNM was the best predictive staging system in multivariate analyses. In our study, TNM and Child-Pugh are the representative systems in predicting survival of HCC patients who undergo surgical resection. Moreover, they are practical and easily assessable in clinical practice.

Download Full-text

High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2017/9503025 ◽

2017 ◽

Vol 2017 ◽

pp. 1-11 ◽

Cited By ~ 10

Author(s):

Miao Zhang ◽

Xuan-zhang Huang ◽

Yong-xi Song ◽

Peng Gao ◽

Jing-xu Sun ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Poor Prognosis ◽

Meta Analysis ◽

Disease Free Survival ◽

Clinicopathological Characteristics ◽

Platelet To Lymphocyte Ratio ◽

Free Survival ◽

Node Negative ◽

Lymphocyte Ratio

Background. We aimed to evaluate the correlation of platelet-to-lymphocyte ratio (PLR) with prognosis and clinicopathological characteristics of breast cancer. Methods. The PubMed and Embase databases were searched. Hazard ratio (HR) with 95% confidence interval (CI) was used to summarize disease-free survival (DFS) and overall survival (OS). Odds ratio (OR) was used to summarize tumor clinicopathological characteristics. Results. High PLR was associated with poor DFS and OS (DFS: HR = 1.47, 95% CI = 1.16–1.85, and Tau2 = 0.070; OS: HR = 1.88, 95% CI = 1.27–2.80, and Tau2 = 0.192). A Galbraith plot indicated that the studies by Allan et al. and Cihan et al. contributed the heterogeneity of DFS and OS, respectively. There were significant differences in the incidence of high PLR between stage II–IV and stage I groups (OR = 1.86, 95% CI = 1.20–2.90, and Tau2 < 0.001), between lymph node-positive and lymph node-negative groups (OR = 1.52, 95% CI = 1.22–1.91, and Tau2 =0.014), and between metastasis-positive and metastasis-negative groups (OR = 4.24, 95% CI = 2.73–6.59, and Tau2 < 0.001). Conclusions. Our results indicated that PLR was associated with poor prognosis of breast cancer and adequately predicted clinicopathological characteristics.

Download Full-text

Biological behavior of HER2+ breast cancer: Differences based in hormone receptor expression.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e12120 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e12120-e12120

Author(s):

Maria Joao Ribeiro Da Silva ◽

Miguel Henriques Abreu ◽

Sergio Xavier Azevedo ◽

Tiago Alpoim ◽

Susana Sousa ◽

...

Keyword(s):

Hormone Receptors ◽

Disease Free Survival ◽

Clinicopathological Characteristics ◽

Receptor Expression ◽

Biological Behavior ◽

Her2 Receptor ◽

Adjuvant Trastuzumab ◽

Her2 Breast Cancer ◽

The Impact

e12120 Background: Breast carcinoma is a heterogeneous disease whose therapeutic approach idepends on the classification into molecular subtypes. Despite the impact the expression of hormone receptors (HR) among patients with overexpression of HER2 is already the target of some studies, there is a lack of analysis in the era of treatment with adjuvant trastuzumab. Methods: This stydy consists in a retrospective analysis of cases of tumors with overexpression of the HER2 receptor (HER2 +), and HR- treated at an oncological center, comparing their biological behavior with cases of HR +/ HER2 + tumors, thus controlling for classic prognosis. Results: We analised a total of 420 patients, of whom 210 with HR+/HER2+ tumors and 210 HR- / HER2 +, with median ages of 52 years and 53 years, respectively. They accounted for 89.5% of cases of stage I to III disease. The groups were balanced in clinical characteristics. There was a higher proportion of undifferentiated and inflammatory tumors in the RH-/ HER2 + group, and in this group higher rates of complete pathological responses to treatment were observed (50.8% vs. 30.0%, p < 0.001). During the follow-up 30 recurrences occurred, 18 in the HR- / HER2 + group, and 12 in the HR + / HER2 +. There was lower disease-free survival in the HR-/HER2 +, on average 69.1 months, compared to 74.3 months in the group HR+/HER2 + (p = 0.001). The first metastatic site involved visceral location in 13 cases (72.2%) in HR- / HER2 + tumors (CNS involved in 8 cases), and in 8 cases (66.6%) in HR + / HER2 + tumors (CNS in 1 case). There was an association between relapse and response to primary systemic treatment (p = 0.003), with no relation demonstrated with other clinicopathological characteristics. In the global sample, there were 28 deaths, corresponding to 17 in the HR-/HER2 +, and 11 in the HR+/HER2 + group. There were significant diferences in OS, showing worse prognosis of HR- disease (mean of 70.7 months vs. 106.6 months, p = 0.001). There was an association of mortality with the presentation as an inflammatory tumor and involvement of the CNS. Conclusions: This study supports the concept of two distinct entities according to the expression in HER2 + disease, justifying therapeutic approaches and eventually different follow-up strategies.

Download Full-text

Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e12587 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e12587-e12587

Author(s):

Shlomit Shachar ◽

Shulamith Rizel ◽

Georgeta Fried ◽

Michelle Leviov ◽

Rinat Yerushalmi ◽

...

Keyword(s):

Disease Free Survival ◽

Recurrence Score ◽

Time Frame ◽

Invasive Disease ◽

Clinicopathological Characteristics ◽

Second Primary ◽

Phase 3 ◽

Free Survival ◽

Node Negative ◽

Disease Free

e12587 Background: In the phase 3 TAILORx study, the first invasive disease-free survival event (in all arms) was often opposite BC or other second primary cancer. Our goal was to investigate differences in the 21-gene RS results between the primary BC and a second primary BC, as well as the association with clinicopathological characteristics. Methods: This analysis of the prospectively-designed CHS registry included all CHS pts with estrogen receptor (ER)+ HER2-negative BC who underwent RS testing between 1/2006 and 6/2019 and for whom ≥2 RS results were identified which were > 1 year apart. Results: Of the 10,244 RS assays ordered in this time frame, 371 involved pts for whom the assay was performed at least twice. Our analysis focused on the 42 pts for whom the assays were performed > 1 year apart. All pts were females; 76% were initially diagnosed with node-negative BC; median (interquartile range [IQR]) age at first diagnosis was 56 (43-64) yrs. Tumor characteristics for the first and subsequent primary BC are presented (Table). The median time (IQR) between the first and latest RS assay was 4.5 (2.9-6.4) yrs. In 28 pts (67%), the latest primary BC was ipsilateral and in 14 (33%) it was contralateral. The median (IQR) difference between the first and latest RS value was 7 (1-12). The second/third primary BC had higher RS than the first BC in the majority (76%) of pts. Higher RS in the latest primary BC (compared to the first primary BC) was more common when the latest primary BC was ipsilateral than when it was contralateral (86% vs 57%, P= 0.04). Conclusions: In ER+ HER2-negative BC pts, second/third primary BC is generally associated with higher RS result (compared to the first primary BC), particularly if the later primary BC is ipsilateral. [Table: see text]

Download Full-text

Prognostic significance of NDRG2 combined with EGFR-sensitizing mutations in lung adenocarcinoma

10.21203/rs.2.14181/v4 ◽

2020 ◽

Author(s):

Bo Yang ◽

Linlin Ji ◽

Yiling Feng ◽

Xiao-Ping Li ◽

Hong-Gang Zhou ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Prognostic Significance ◽

Growth Factor Receptor ◽

Disease Free Survival ◽

Progression Free Survival ◽

Lung Parenchyma ◽

Clinicopathological Characteristics ◽

Free Survival ◽

Positive Correlations ◽

Lung Puncture

Abstract Background: N-myc downstream-regulated gene 2 (NDRG2) plays a substantial role in lung adenocarcinoma (LUAD). Epidermal growth factor receptor (EGFR)-sensitizing mutation could significantly improve prognosis in patients with LUAD. Here, we aimed to elucidate the prognostic value of NDRG2 combined with EGFR-sensitizing mutations in patients with LUAD. Methods: Lung parenchyma specimens obtained during surgery or CT-guide percutaneous lung puncture biopsy for the NDRG2 protein and EGFR genomic testing were obtained. Associations between NDRG2/EGFR and clinicopathological characteristics of patients with LUAD were extracted from the Tianjin First Central Hospital in China between June 2013 and June 2014. Results: The expression of NDRG2 was significantly decreased in patients with LUAD. Expressions of NDRG2 and EGFR-sensitizing mutations showed positive correlations with survival. Expression of NDRG2 and EGFR-sensitizing mutations were associated with the longer overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). Advanced stages were significantly associated with low expression of NDRG2. In multivariate analysis, compared with other patients, NDRG2 (+)/EGFR (+) was independently associated with prolonged OS and PFS. Conclusion: NDRG2 combined with EGFR-sensitizing mutations might be valuable markers to evaluate the prognosis of LUAD patients.

Download Full-text

Recurrence after Complete Cryoablation of Colorectal Liver Metastases: Analysis of Prognostic Features

The American Surgeon ◽

10.1177/000313480607200503 ◽

2006 ◽

Vol 72 (5) ◽

pp. 382-390

Author(s):

Tristan D. Yan ◽

David R. Nunn ◽

David L. Morris

Keyword(s):

Liver Metastases ◽

Colorectal Liver Metastases ◽

Multivariate Analyses ◽

Univariate Analysis ◽

Disease Free Survival ◽

Free Survival ◽

Prognostic Features ◽

Observational Cohort ◽

Disease Free

This study critically evaluated the prognostic determinants for disease-free survival (DFS) after cryoablation for colorectal liver metastases. An observational cohort study of prospectively collected data on 135 patients who underwent cryoablation with or without resection for colorectal liver metastases was performed. Univariate and multivariate analyses were used to determine the prognostic factors for overall DFS, cryosite DFS, remaining liver DFS, and extrahepatic DFS. Overall, 115 patients (85%) developed recurrence at the cryosite (44%), and the remaining patients developed recurrence at the liver (62%) and extrahepatic site (71%). In univariate analysis, pre-operative and postoperative carcinoembryonic antigen (CEA) were significant for overall DFS. Distribution of metastases, operation type, total number of metastases, number of cryotreated metastases, largest size of cryotreated metastasis, and postoperative CEA were significant for cryosite DFS. The number of cryotreated metastases and postoperative CEA were significant for remaining liver DFS. The largest size of cryotreated metastasis, and preoperative and postoperative CEA were significant for extrahepatic DFS. In multivariate analysis, resection plus cryoablation, ≤7 liver metastases and ≤3 cm cryotreated metastasis were independently associated with an improved cryosite DFS. Preoperative CEA of ≤5 ng/mL was independently associated with an improved overall and extrahepatic DFS. The role of CEA in colorectal metastasis is important. Resection plus cryoablation rather than cryoablation alone should be used for larger lesions.

Download Full-text

An International Multi-Institutional Study of Double Cord Blood Transplantation in a Racially Diverse Population.

Blood ◽

10.1182/blood.v110.11.2017.2017 ◽

2007 ◽

Vol 110 (11) ◽

pp. 2017-2017

Author(s):

Karen Ballen ◽

Brian Wang ◽

Joseph Rosenthal ◽

Auayporn Nademanee ◽

Chatchada Karanes ◽

...

Keyword(s):

Cord Blood ◽

Multivariate Analyses ◽

Cord Blood Transplantation ◽

Disease Free Survival ◽

Racially Diverse ◽

P Values ◽

Free Survival ◽

Cell Dose ◽

Blood Transplantation ◽

Disease Free

Abstract Cord blood (CB) is an alternative stem cell source for patients, but single CB products may not contain sufficient cell dose for cord blood transplantation (CBT) of adults. Double cord blood transplantation (DCBT) has been used to increase the cell dose, but the majority of reported patients have been Caucasian. We conducted a retrospective analysis of 89 consecutive DCBT recipients who received at least one CB product from the StemCyte CB banks. The median age was 20 years (range 1–63), with 58% over age 18, and the median weight was 60 kg (range 11–137), with 70% ≥ 50 kg. Diagnoses were: 29 ALL, 23 AML, 10 Thalassemia, 6 CML, 5 MDS, 4 AA, 3 lymphoma, and 9 others. 33% had IBMTR advanced disease status, 28% intermediate, 18% early, and 21% unknown status for the leukemia/lymphoma/MDS cases. 70% of the recipients with known race were non-Caucasian (NC) with 35 Asians (A), 24 Caucasians (C), 9 African Americans, 8 Hispanics, 3 Native Americans, 10 others. Patients were treated with a variety of conditioning regimens (33% reduced intensity) at 39 U.S. and international centers on 4 continents with 37% at non-US centers. Thirty-seven patients (42%) received both units as plasma depleted cord blood products. CB product characteristics were as follows: median pre-freeze TNC dose 3.8×107/kg, median pre-freeze CD34+ dose 1.4×105/kg. The median time to neutrophil (ANC500) engraftment was 21.5 days and the median time to platelet (Plt) 20K and 50K engraftment were 42 and 59 days respectively. Kaplan-Meier (KM) estimates of 100-day transplant related mortality (TRM), 1-year overall (OS) and disease free survival (DFS) were 37±6%, 50±6%, and 37±6% respectively. Causes of death include infection (26%), relapse (23%), multi-organ failure (16%), GvHD (2%), and other (33%). Engraftment correlated with cell dose and disease risk status in univariate analysis. Survival correlated with higher pre-freeze TNC dose (p=.03), higher pre-freeze CD34+ dose (p=.04), and non-washed CB (p=.01). Survival, disease-free survival, ANC 500, plt 20K, and 50K engraftment, and TRM were not different between C and NC or between A and Non-Asians (NA) in multivariate analyses. 1-year OS for C and NC patients were 48% and 54% respectively (p=.24), with DFS of 35% and 40% (p=.32), respectively. In conclusion, this multi-centered international study shows that 1) DCBT can be performed effectively on a racially diverse patient population, 2) Survival and other outcome measures were similar between C and NC or between A and NA patients in multivariate analyses, 3) Cell dose remains important for engraftment even with DCBT. ANC500 Plt 20K 1 Yr Relapse 100-Day & 1-Yr TRM 1-Yr OS 1-Yr DFS * W = Washed CB, NW = Unwashed, CI = Cumulative Incidence; P-values from multivariate Cox Regression model adjusting for recipient weight, malignancy, and # of StemCyte units involved in DCBT. % & Median Days to Engraftment CI 83±7 KM 90±4 21.5 days CI 57±7 KM 78±7 42days 31±7 21±4 37±6 50±6 37±6 P-values* C vs. NC (W) .34 .86 .86 .87 .92 .86 C vs. NC (NW) .06 .59 .90 .35 .72 .92 A vs. NA (W) .43 .15 .80 .33 .13 .66 A vs. NA (NW) .69 .37 .75 .70 .30 .30

Download Full-text

An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis

Disease Markers ◽

10.1155/2017/1053125 ◽

2017 ◽

Vol 2017 ◽

pp. 1-10 ◽

Cited By ~ 15

Author(s):

Xuan-zhang Huang ◽

Wen-jun Chen ◽

Xi Zhang ◽

Cong-cong Wu ◽

Chao-ying Zhang ◽

...

Keyword(s):

Colorectal Cancer ◽

Poor Prognosis ◽

Meta Analysis ◽

Disease Free Survival ◽

Clinicopathological Characteristics ◽

Platelet To Lymphocyte Ratio ◽

Poor Overall Survival ◽

Cancer Specific Survival ◽

Free Survival ◽

Lymphocyte Ratio

Background.The aims of this study were to evaluate the clinicopathological and prognostic values of platelet-to-lymphocyte ratio (PLR) in colorectal cancer (CRC).Methods.The PubMed and Embase databases and the references of relevant studies were systematically searched. This study was performed with hazard ratios (HRs) and odd ratios (ORs) with corresponding 95% confidence intervals (CIs) as effect measures.Results.Our results indicated that elevated PLR was associated with poor overall survival (HR = 1.46, 95% CI = 1.23–1.73), disease-free survival (HR = 1.64, 95% CI = 1.17–2.30), cancer-specific survival (HR = 1.30, 95% CI = 1.12–1.51), and recurrence-free survival (HR = 1.38, 95% CI = 1.09–1.74) in CRC. For the clinicopathological characteristics, our results indicated that there were differences in the rate of elevated PLR between stages III/IV and I/II groups (OR = 1.38, 95% CI = 1.01–1.88), pT3/T4 and pT1/T2 groups (OR = 1.82, 95% CI = 1.03–3.20), and poor differentiation and moderate/well differentiation (OR = 2.59, 95% CI = 1.38–4.84).Conclusions.Our results indicated that elevated PLR predicted poor prognosis and clinicopathological characteristics in CRC and PLR is a convenient and low-cost blood-derived prognostic marker for CRC.

Download Full-text

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

BMC Cancer ◽

10.1186/s12885-021-08140-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Katharina Kriegsmann ◽

Christiane Zgorzelski ◽

Thomas Muley ◽

Petros Christopoulos ◽

Michael Thomas ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Neuroendocrine Differentiation ◽

Disease Free Survival ◽

Morphological Features ◽

Free Survival ◽

Significant Difference ◽

Disease Free

Abstract Background Synaptophysin, chromogranin and CD56 are recommended markers to identify pulmonary tumors with neuroendocrine differentiation. Whether the expression of these markers in pulmonary adenocarcinoma and pulmonary squamous cell carcinoma is a prognostic factor has been a matter of debate. Therefore, we investigated retrospectively a large cohort to expand the data on the role of synaptophysin, chromogranin and CD56 in non-small cell lung cancer lacking morphological features of neuroendocrine differentiation. Methods A cohort of 627 pulmonary adenocarcinomas (ADC) and 543 squamous cell carcinomas (SqCC) lacking morphological features of neuroendocrine differentiation was assembled and a tissue microarray was constructed. All cases were stained with synaptophysin, chromogranin and CD56. Positivity was defined as > 1% positive tumor cells. Data was correlated with clinico-pathological features including overall and disease free survival. Results 110 (18%) ADC and 80 (15%) SqCC were positive for either synaptophysin, chromogranin, CD56 or a combination. The most commonly positive single marker was synaptophysin. The least common positive marker was chromogranin. A combination of ≤2 neuroendocrine markers was positive in 2–3% of ADC and 0–1% of SqCC. There was no significant difference in overall survival in tumors with positivity for neuroendocrine markers neither in ADC (univariate: P = 0.4; hazard ratio [HR] = 0.867; multivariate: P = 0.5; HR = 0.876) nor in SqCC (univariate: P = 0.1; HR = 0.694; multivariate: P = 0.1, HR = 0.697). Likewise, there was no significant difference in disease free survival. Conclusions We report on a cohort of 1170 cases that synaptophysin, chromogranin and CD56 are commonly expressed in ADC and SqCC and that their expression has no impact on survival, supporting the current best practice guidelines.

Download Full-text

Prognostic Value of Tumour Size in Colon Cancer – Smaller is Better?

10.21203/rs.3.rs-566870/v1 ◽

2021 ◽

Author(s):

Siyi Lu ◽

Bingyan Wang ◽

Zhenzhen Liu ◽

Fei Li ◽

Yongqu Lu ◽

...

Keyword(s):

Colon Cancer ◽

Prognostic Value ◽

Tumour Size ◽

Disease Free Survival ◽

Tumour Microenvironment ◽

Clinicopathological Characteristics ◽

Free Survival ◽

Small Tumour ◽

Mismatch Repair Status ◽

Large Tumour Size

Abstract Background: The prognostic value of tumour size in colon cancer remains controversial. This study aimed to reveal the correlation between tumour size and prognosis of colon cancer.Methods: A total of 498 patients with colon cancer were included in this study. The correlation of tumour size with prognosis, mismatch repair status and other clinicopathological characteristics as well as tumour microenvironment was analysed.Results: For stage IIA microsatellite stable (MSS) colon cancer, tumours sized <3.5 cm and ≥5 cm were associated with a poorer disease free survival (DFS) compared with tumours sized between 3.5 and 5 cm (p=0.002). Small tumour size (HR=5.098, p=0.001) and large tumour size (HR=2.749, p=0.029) were found to be independent prognostic factors for stage IIA MSS colon cancer. Moreover, high expression of transgelin (TAGLN), a marker of cancer-associated fibroblasts (CAFs), was found to be an independent prognostic factor for poorer DFS (HR=9.651, p=0.009), which was also associated with smaller tumour size (p=0.027).Conclusion: Small (<3.5 cm) and large (≥5 cm) tumour sizes are associated with decreased DFS in stage IIA MSS colon cancer. Enrichment of TAGLN+ CAFs is associated with decreased DFS and small tumour size.

Download Full-text